IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:02 2024-07-16 am EDT			5-day change	1st Jan Change
7 ^GBX	0.00%		0.00%	-44.00%

Jun. 19	Ixico Bags Over GBP1 Million Contract for Parkinsonian Disorder Study	MT
Jun. 19	AIM WINNERS & LOSERS: Ixico and Light Science Technologies win deal	AN

IXICO plc Provides Earnings Guidance for the Year Full Year of 2021 and 2022

August 06, 2021 at 02:00 am EDT

IXICO plc provided earnings guidance for the year full year of 2021 and 2022. For the full year 2021, the company expects to deliver £8.7m in revenues. For the year 2022, The company anticipates returning to a double-digit revenue growth trajectory as its 2022 financial year progresses.

Latest news about IXICO plc

Ixico Bags Over GBP1 Million Contract for Parkinsonian Disorder Study	Jun. 19	MT
AIM WINNERS & LOSERS: Ixico and Light Science Technologies win deal	Jun. 19	AN
Ixico shares jump as wins new pharma contract worth over GBP1 million	Jun. 19	AN
IXICO plc Announces New Pharma Client Contract Valued in Excess of £1 Million for A Study of A Parkinsonian Disorder	Jun. 19	CI
Ixico wins deal; United Oil & Gas settles debt	May. 23	AN
IXICO plc Signs Contract with Global Alzheimer's Platform Foundation to Support Bio-Hermes 2 Trial	May. 23	CI
EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss	May. 21	AN
Transcript : IXICO plc, H1 2024 Earnings Call, May 21, 2024	May. 21
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP2.5M	May. 21	MT
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Loss GBX-2.92	May. 21	MT
IXICO plc Reports Earnings Results for the Half Year Ended March 31, 2024	May. 21	CI
Ixico inks supply agreement with Life Molecular Imaging for Neuraceq	Apr. 15	AN
IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer	Apr. 15	CI
Ixico inks collaboration with IMEKA Solutions	Apr. 03	AN
IXICO plc Announces Collaboration Agreement with IMEKA Solutions Inc. to Provide Access to Imeka's Suite of Services for White Matter Imaging deployed in Alzheimer's Disease and Multiple Sclerosis Clinical Trials, Amongst Other CNS Indications	Apr. 03	CI
Ixico shares fall 20% as revenue to decline, hit by delays to projects	Mar. 13	AN
AIM WINNERS & LOSERS: Woodbois rises as plots Mozambique exit	Mar. 13	AN
FTSE 100 slips but CAC and DAX hit record highs	Mar. 13	AN
Ixico CEO Cerroni to retire by end of 2024; starts succession search	Jan. 12	AN
Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024	Jan. 12	CI
Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024	Jan. 12	CI
Transcript : IXICO plc, 2023 Earnings Call, Dec 05, 2023	Dec. 05
EARNINGS AND TRADING: Ixico revenue falls, Solid State boosts profit	Dec. 05	AN
IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 05	CI
Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees	23-10-05	CI

Chart IXICO plc

Duration

Period

More charts

Company Profile

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

Sector

Biotechnology & Medical Research

Calendar

2024-12-02 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for IXICO plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IXICO PLC	-44.00%	4.39M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research